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The retrospective cohort study for survival rate in patients 
with advanced hepatocellular carcinoma receiving 
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Background/Aims: This study was conducted to investigate the assessment of treatment efficacy of radiotherapy (RT) and other 
therapeutic modalities compared with palliative care only for treatment with advanced hepatocellular carcinoma (HCC). 
Methods: From 2002 to 2010, based on the case of 47 patients with advanced HCC, we have investigated each patients' 
Child-Pugh's class, ECOG performance, serum level of alpha fetoprotein and other baseline characteristics that is considered to 
be predictive variables and values for prognosis of HCC. Out of overall patients, the 29 patients who had received RT were 
selected for one group and the 18 patients who had received only palliative care were classified for the other. The analysis in 
survival between the two groups was done to investigate the efficacy of RT. Results: Under the analysis in survival, the mean 
survival time of total patients group was revealed between 30.1 months and 45.9 months in RT group, while it was 4.8 months in 
palliative care group, respectively. In the univariate analysis for overall patients, there were significant factors which affected 
survival rate like as follows: ECOG performance, Child-Pugh's class, the tumor size, the type of tumor, alpha fetoprotein, 
transarterial chemoembolization, and RT. The regressive analysis in multivariate Cox for total patients. No treatment under 
radiotherapy and high level of Child-Pugh's class grade were independent predictors of worse overall survival rate in patients. 
In contrast, for the subset analysis of the twenty-nine patients treated with radiotherapy, the higher serum level of alpha 
fetoprotein was an independent predictors of worse overall survival rate in patients. Conclusions: We found that the survival of 
patients with advanced HCC was better with radiotherapy than with palliative care. Therefore, radiotherapy could be a good 
option for in patients with advanced HCC. (Korean J Hepatol 2011;17:189-198)
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INTRODUCTION
Pursuant to the the data of National Statistical Information 
Service of the Ministry for Health, Welfare and Family Affairs in 
2009, hepatocellular carcinoma (HCC) is ranked the fourth in the 
incidence rate of cancer like as follws : gastric cancer, colorectal 
cancer and lung cancer. In addition, the annual report of Statistics 
Korea on death causes in 2008 showed that HCC recorded the 
second highest mortality rate, showing 16.4% of the total death 
caused by cancer only after lung cancer.
1 Because it showed 
relatively advanced stages at diagnosis in a variety of cases, 
radical hepatic resection was available only in limited cases and 
liver cirrhosis as a underlying disease which occurred in many 
cases along with multiplicity.
2,3
As radiotherapeutic technology has currently progressed, 
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prevent the recurrence and to increase the survival rate after 
nonsurgical treatments of advanced HCC.
4 Radiotherapy is 
applied to HCC patients who cannot be treated with surgical 
resection or with a radical treatment such as a locoregional 
treatment and transarterial chemoembolization (TACE). It is 
mainly executed for patients with liver function of A or upper B 
in Child-Pugh's classification, and its response rate and median 
survival time were reported to be 40-90% and 10-25 months, 
respectively.
4 The indication of radiotherapy for safe treatment, 
which provokes only a few side effects, is that the volume of 
the tumor is less than one third of the total liver volume.
5 
Furthermore, the indications of extended radiotherapy show that 
it is less than two thirds or 70% of the total liver volume
6,7 and 
that the volume irradiated with 30 Gy is less than 60% of the total 
liver volume in dose-volume analysis.
8 Providing a high-dose 
irradiation as a local irradiation, not the whole liver irradiation, 
has been identified, which has been continuously reported that 
the combination therapy of radiotherapy and chemotherapy or 
TACE for HCC works favorably.
9-11 What is more, in case of the 
patients who are not under other treatments or associating with 
portal vein thrombosis,
12-15 radiotherapy was safe and effective 
to raise the survival rate.
16 The radiotherapy had the effect of 
relieving cancer pain, improving symptoms through the decrease 
of lesions, lengthening the survival time in the circumstances 
with the biliary obstruction of a tumor associated with 
jaundice,
17,18 and extending the survival time in patients with 
abdominal lymph node metastasis.
19 However, even now it is not 
uncommon that only best palliative care can be maintained when 
it is hard to treat advanced HCC actively or when the general 
condition of a HCC patient is not appropriate. As a result, this 
study is focused on analyzing whether radiotherapy leads to a 
significant difference in the survival rate, comparing not only 
advanced HCC patients who have underwent treatments based 
on radiotherapy but also with those who have received only 
conservative ones.
PATIENTS AND METHODS
Patients
The critical point of this retrospective research was the 
medical record of overall 47 patients under advanced HCC of 
Barcelona Clinic Liver Cancer (BCLC) stage C or D diagnosed 
at Chungnam National University Hospital from January 2002 to 
March 2010.
20 The patients who recorded C in Child-Pugh's 
classification or with a diffuse tumor were excluded.
21 Diagnosis 
criteria of HCC were hepatic nodules which were confirmed 
through liver ultrasonography and others, alpha fetoprotein 
(AFP) of over 200 ng/mL and findings which were appropriate to 
HCC in one of the contrast-enhanced dynamic computerized 
tomography (CT) and contrast-enhanced dynamic magnetic 
resonance image (MRI). When AFP was less than 200 ng/mL, 
the patients were diagnosed as HCC, who showed appropriate 
features to HCC in two or three out of three imaging studies of 
the contrast-enhanced dynamic CT, the contrast-enhanced 
dynamic MRI and the hepatic angiography. Those results were 
based on the criteria which were provided by “Practice guideline 
for management of HCC 2009” jointly under the definition of the 
Korean Liver Cancer Study Group and National Cancer Center.
22 
Out of the 47 patients, 29 were selected by excluding patients 
with distant metastasis. They completed their scheduled 
radiotherapy for one or more lesions among primary HCC, local 
lymph node metastasis and portal vein thrombosis sites without 
early discontinuance or delay from December 2005 to September 
2009. Except for them, the other 18 received only palliative care. 
Under the definition of WHO, palliative care means the cases of 
receiving only passive treatments to improve the survival rate 
after the diagnosis of HCC.
23 It enables patients to improve the 
quality of life, assisting them from physical, mental and spiritual 
aspects until they face death, which leads them to accept the 
death as a normal process with reducing distress and pain rather 
than lengthening their life artificially.
The clinical and biochemical data of patients at diagnosis were 
investigated, which included the existence of ascites and hepatic 
encephalopathy and Child-Pugh's classification based on 
albumin, prothrombin time and total bilirubin. Others were also 
examined as followings: AFP, hepatitis B, hepatitis C, 
Eastern Cooperative Oncology Group (ECOG) score,
24 body 
mass index (BMI), and the history of smoking and drinking. 
According to the causes of liver cirrhosis, patients were 
classified into alcoholic, hepatitis B- and hepatitis C- related 
and idiopathic one. Liver cirrhosis was diagnosed by 
synthesizing the degree of decompensated features of the 
former liver, such as ascites, hepatic encephalopathy, jaundice 
and upper gastrointestinal bleeding, the results of clinical and 
clinicopathological examinations and medical references which 
were suggested as portal hypertension on endoscopy. As 
shown in Table 1, the characteristics of the total subjects are 
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Table 1. Patients’ characteristics
Characteristics Total patients (n=47) Radiotherapy (n=29) Palliative care (n=18) P-value
Age (years, mean±S.D.) 63.3±9.4 62.2±9.2 64.9±9.7 0.353
  <60, n (%) 15 11 (73.3%) 4 (26.7%)
0.343
  ≥60, n (%) 32 18 (56.2%) 14 (43.8%)
Gender 0.473
  Male, n (%) 37 24 (64.9%) 13 (35.1%)
  Female, n (%) 10 5 (50.0%) 5 (50.0%)
ECOG performance 0.009
  1 40 28 (70.0%) 12 (30.0%)
  2  7 1 (14.3%) 6 (85.7%)
Alcohol drinking 0.130
  Yes 28 20 (71.4%) 8 (28.6%)
  No 19 9 (47.4%) 10 (52.6%)
Smoking (packyears) mean±S.D. 14.7±17.1 16.6±18.3 11.8±14.8 0.357
BMI (kg/m
2) mean±S.D. 23.5±3.1 24.3±3.1 22.3±2.8 0.033
HBsAg 0.763
  Positive 28 18 (64.3%) 10 (35.7%)
  Negative 19 11 (57.9%) 8 (42.1%)
Anti-HCV 0.025
  Positive 6 1 (16.7%) 5 (83.3%)
  Negative 41 28 (68.3%) 13 (31.7%)
Liver cirrhosis 37 21 (56.8%) 16 (43.2%) 0.277
Etiology of cirrhosis 0.088
  HBV 25 16 (64.0%) 9 (36.0%)
  HCV 4 0 (0%) 4 (100.0%)
  Alcoholic 6 4 (66.7%) 2 (33.3%)
  Idiopathic 2 1 (50.0%) 1 (50.0%)
Child-Pugh's class 0.010
  A 34 25 (73.5%) 9 (26.5%)
  B 13 4 (30.8%) 9 (69.2%)
Data represents patients number (%). Pearson's chi-squared test, the independent two-sample t-test, or Fisher's exact test were used 
for statistical analysis. 
SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; HBsAg, hepatitis B viral antigen; Anti-HCV, anti-hepatitis C viral 
antibody; HBV, hepatitis B virus; HCV, hepatitis C virus.
Types of HCC
In order to identify the most important variables on this 
research, the types of HCC were divided into massive, multino-
dular, and single nodular ones by following the classification 
of Yuki et al
21 Regardless of the existence of a satellite nodule, 
the massive type can be defined into a large single mass. 
Multinodular and single nodular ones consist of two or more 
separated nodules and single nodule, respectively. In addition, 
HCC was analyzed into classifying under the size of the tumor 
and the existence of portal vein thrombosis. The size of the tumor 
was measured on CT image, which was done for single nodular 
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Table 2. Tumor characteristics and treatments
Characteristics Total patients (n=47) Radio-therapy (n=29) Palliative care (n=18) P-value
Tumor type 0.215
  Massive 8 3 (37.5%) 5 (62.5%)
  Multinodular 26 16 (61.5%) 10 (38.5%)
  Single nodular 13 10 (76.9%) 3 (23.1%)
The number of tumor 0.365
  <5 28 19 (67.9%) 9 (32.1%)
  ≥5 1 9 1 0( 5 2 . 6 % ) 9( 4 7 . 4 % )
The size of tumors (cm) <0.001
  <5 23 20 (87.0%) 3 (13.0%)
  ≥5 24 9 (37.5%) 15 (62.5%)
Okuda stage <0.001
  1 2 8 2 3( 8 2 . 1 % ) 5( 1 7 . 9 % )
  2 12 3 (25.0%) 9 (75.0%)
  3 7 3( 4 2 . 9 % ) 4( 5 7 . 1 % )
BCLC stage 0.003
  C 39 28 (71.8%) 11 (28.2%)
  D 8 1( 1 2 . 5 % ) 7( 8 7 . 5 % )
AFP (ng/mL)
  Mean 7669.2±28 046.3 3221.1±9128.4 10731.6±32 880.8 0.759
  <200 30 20 (66.7%) 10 (33.3%)
0.533
  ≥200 17 9 (52.9%) 8 (47.1%)
Lymph node 0.739
  Yes 13 9 (69.2%) 4 (30.8%)
  No 34 20 (58.8%) 14 (41.2%)
Potal vein thrombosis 1.000
  Yes 28 17 (60.7%) 11 (39.3%)
  No 19 12 (63.2%) 7 (36.8%)
TACE <0.001
  Yes 25 25 (100.0%) 0 (0%)
  No 22 4 (18.2%) 18 (81.8%)
Chemo-therapy 0.069
  Yes 6 6 (100.0%) 0 (0%)
  No 41 23 (56.1%) 18 (43.9%)
Operation 0.018
  Yes 9 9 (100.0%) 0 (0%)
  No 38 20 (52.6%) 18 (47.4%)
Data represents patients number (%). Pearson's chi-squared test or Mann-Whitney U-test were used for statistical analysis. 
BCLC, Barcelona Clinic Liver Cancer; AFP, alpha fetoprotein; TACE, transarterial chemoembolization.
multinodular one with the sum of the two longest diameter of the 
nodules. Each size was classified into two groups of less than 5 
cm and 5 or more than 5 cm. Meanwhile, portal vein thrombosis 
was examined through CT or hepatic arteriography. The detailed 
HCC which is related to morphologic classification, stages and 
portal vein invasion of the subjects are presented in Table 2.
Treatments of HCC
While clinical trials are under way for this study, 29 patients 
have underwent radiotherapy for HCC, including both of patients Hyuk Soo Eun, et al. Survival rate on radiotherapy compared with palliative care in HCC  193
who have received only radiotherapy and those with TACE, 
hepatic resection, chemotherapy or combination therapy. Out of 
the 29 patients, 24 were treated only with radiotherapy during the 
treatment, while the others were done with radiotherapy and 
chemotherapy. 28 patients received other treatments before 
radiotherapy, and 17 got an additional treatment after it. For 
TACE, according to priority of treatment procedures, a catheter 
was inserted to the hepatic artery through arteriopuncture of the 
ingunial area, the combination of 10 ml lipiodol and 50 mg 
doxorubicin as antitumor agents was injected into the hepatic 
artery selectively, and then gelfoam was injected lastly.
The dose for radiotherapy was not only determined by 
individualizing patients under their general conditions and 
stages, but they were also irradiated by using a 10 megavolt 
(MV) linear accelerator. The patients under the radiotherapy 
were irradiated with daily dose of 2Gy for five days per week. 
Overall exposure dose was 45.9±10.6Gy in average, and 3D 
conformal radiotherapy was utilized for the irradiation. The 
radiotherapy was performed for one patient as initial treatment 
and for the other 28 ones as rescue therapy.
Evaluation of response to treatment
Response to the treatment was evaluated through CT for a 
follow-up in 6-8 weeks after the radiotherapy. There were four 
significant cases associated with the size of tumor and portal vein 
thrombosis. The definitions for each case are followed: 
Complete response (CR) was tabulated without any tumor and 
portal vein thrombosis. Partial response (PR) was measured into 
the decrease in the longest diameter of the largest nodule or the 
sum of the longest diameter of the largest two nodules by over 
50%. No response (NR) was defined into the decrease by less 
than 50% or no change and the increase in the number of lumps. 
Progressive disease (PD) was classified as the increase in the size 
of a tumor by over 25%.
25,26 The responder group was the 
addition of CR and PR groups and the non-responder group was 
that of NR and PD groups.
25
Statistical analysis
The frequency and proportion of patients receiving each 
treatment modality were calculated and tabulated with SPSS 
version 13 (SPSS Inc.)
® for statistical analysis. The results were 
presented with mean value and standard deviation, and, if 
necessary, percent (%) was used with each individual number. 
Overall survival time was defined as the period from the 
diagnosis date to the death of date for patients expired, and from 
the diagnosis date to the date of the last follow-up for surviving 
patients. To compare basic characteristics of the radiotherapy 
and the palliative care groups, Pearson's chi-squared test and 
independent two-sample t-test were performed. When the cases 
with an expected frequency of less than 5 was over 25% of the 
contingency table, Fisher's exact test was applied. As the 
variation of AFP was severer in standard deviation compared to 
its mean value, Mann-Whitney U-test or a non-parametric test 
was used. The survival rate was analyzed with Kaplan-Meier 
method, and a log-rank test was conducted to compare and 
analyze the survival curve by each factor. To exclude the 
correlation among factors which influence the survival rate 
significantly, multivariate analysis was performed with Cox 
regression analysis, using Cox’s proportional hazard model. A 
P-value of <0.05 was considered to be significant statistically.
RESULTS
Clinical and clinicopathological characteristics
The number of all the patients registered for this study was 
totally 47, who were 37 males and 10 females under the average 
of 63.3±9.4 years old. At the time of diagnosis on HCC, 37 
(78.7%) patients had liver cirrhosis. Out of the liver cirrhosis 
patients, 24 (64.9%) and 13 (35.1%) were recorded as A and B 
in Child-Pugh's classification, respectively. 
As shown in Table 1, BMI was not different significantly 
between the radiotherapy and the conservative treatment groups 
by recording 24.3±3.1 kg/m
2 and 22.3±2.8 kg/m
2, respectively. 
As for morphological characteristics of tumors, massive, 
multinodular and single nodular types were found in 8 (17.0%), 
26 (55.3%) and 13 (27.7%) patients each. The mean AFP was 
7669.2±28
 046.3 ng/mL (1.5-175,000 ng/mL). While AFP of 12 
patients was within the normal range (<10 ng/mL), AFP of 18 
patients was over 200 ng/mL (Table 2).
Comparison of characteristics between the 
radiotherapy and the palliative care groups, and 
response to radiotherapy
When the 29 patients undergoing radiotherapy were compared 
and analyzed with the 18 receiving only palliative care, the rate 
of patients who recorded two points in ECOG performance status 
was significantly higher (P=0.009), the rate of hepatitis C 
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Table 3. Univariate analysis of overall survival of all patients (n=47)
Variable N Mean survival (months) P-value
Age (years) <60/≥60 15/32 31.2/30.2 0.938
Sex M/F 37/10 30.3/29.0 0.978
BMI ≤23.0/>23.0 18/29 31.4/30.9 0.979
ECOG 1/2 40/7 34.0/8.0 0.005
Child-Pugh's class A/B 34/13 38.4/9.8 <0.001
The number of tumor <5/≥5 28/19 24.3/40.5 0.265
Tumor size (cm) <5/≥5 23/24 46.6/11.5 <0.001
Type of tumor Massive/multi-nodular/single nodular 8/26/13 7.5/33.1/42.0 0.010
AFP (ng/mL) <200/≥200 30/17 37.5/12.8 0.023
Portal vein thrombosis Yes/No 28/19 23.0/40.7 0.101
Radiotherapy Yes/No 29/18 45.9/4.8 <0.001
TACE Yes/No 25/22 48.1/10.0 <0.001
Alcohol drinking Yes/No 28/19 27.5/34.5 0.788
HBsAg Yes/No 28/19 33.4/24.9 0.664
Anti-HCV Yes/No 6/41 15.8/31.5 0.395
Liver cirrhosis Yes/No 37/10 28.2/33.4 0.415
Operation Yes/No 9/38 46.8/26.2 0.107
Chemotherapy Yes/No 6/41 42.2/27.9 0.224
Kaplan-Meier method or log-rank test were used for statistical analysis. 
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; AFP, alpha fetoprotein; TACE, transarterial chemoembolization; HBsAg, 
hepatitis B viral antigen; Anti-HCV, anti-hepatitis C viral antibody.
classification was higher (P=0.010), in the palliative care group 
than in the radiotherapy group. In addition, patients with a large 
tumor were observed more frequently in the palliative care group 
(P<0.001) and both of Okuda and BCLC stages were advanced 
in the palliative care group (P<0.001, P=0.003). Except for them, 
as shown in Table 1 and 2, the other factors did not have any 
significant differences statistically between the two groups. The 
radiotherapy group was divided into the responder group under 
CR (n=4, 13.8%) and PR (n=7, 24.1%) and the non-responder 
group under NR (n=8, 27.6%) and PD (n=10, 34.5%), including 
11 (37.9%) and 18 (62.1%) out of the 29 patients, respectively.
Survival analysis
The follow-up period for overall patients to be observed was 
25.0 (1-110) months in average. The mean survival time of 
the total patients was 30.1 (19.8-40.4) months, and that of the 
radiotherapy and the palliative care groups recorded 45.9 
(32.0-59.8) and 4.8 (2.0-7.6) months, respectively (P<0.001). 
Univariate analysis of all the subjects revealed that the 
group recording two points of ECOG performance status 
showed much shorter survival period than that with one point 
and the difference was significant statistically (8.0 vs. 34.0) 
(P=0.005). As the mean survival time of the groups with 
Child-Pugh's classification A and B was respectively 38.4 
and 9.8 months, higher grade was significantly associated 
with shorter survival time (P<0.001). The mean survival time 
of the groups with the size of a tumor nodule of less than 5 cm 
and over 5 cm was 46.6 and 11.5 months each, so the group 
with a larger nodule had shorter survival time (P<0.001). In 
addition, the mean survival time of the massive type and 
the multinodular type was reduced significantly, comparing 
to that of the single nodular type (7.5 vs. 33.1 vs. 42.0 months) 
(P=0.010). The group with AFP of over 200 ng/mL had 
significantly shorter survival time than that with AFP of less 
than 200 ng/mL (12.8 vs. 37.5 months) (P=0.023). For the other 
factors except for them, there was no significant difference in the 
survival time (Table 3). 
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Figure 1. Comparison of overall survival of patients with 
advanced hepatocellular carcinoma treated with radiotherapy or 
palliative care based on Child-Pugh classes A and B (Kaplan-Meier
method, log-rank test, P<0.001).
Table 4. Multivariate analysis of overall survival of all patients (n=47)
Variables Wald Hazard ratio (95% confidence interval) P-value
Gender (female vs. male) 1.03 1.74 (0.60-5.03) 0.310
Age (<60 vs. ≥60) 0.02 1.07 (0.46-2.49) 0.879
ECOG (1 vs. 2) 0.27 0.76 (0.27-2.15) 0.602
AFP (ng/mL) (<200/≥200) 2.55 2.00 (0.86-4.52) 0.110
TACE (No vs. Yes) 0.81 0.55 (0.15-2.01) 0.367
Radiotherapy (No vs. Yes) 7.40 0.12 (0.03-0.55) 0.007
Tumor size (cm)  0.78 1.65 (0.54-5.02) 0.378
Type of tumor 1.04 0.600
Single nodular vs. massive 0.46 1.62 (0.40-6.47) 0.499
Single nodular vs. multinodular 0.01 0.95 (0.34-2.66) 0.922
Child-Pugh's class (A vs. B) 5.58 3.15 (1.22-8.18) 0.018
Cox regression analysis was used for statistical analysis. 
ECOG, Eastern Cooperative Oncology Group; AFP, alpha fetoprotein; PVT, portal vein thrombosis; TACE, transarterial chemoembolization.
into Child-Pugh's classification A and B groups, respectively 
(RT-A, RT-B, palliative care-A and palliative care-B) the 
survival analysis was conducted. The mean survival time of 
RT-A, RT-B, palliative care-A and palliative care-B groups was 
49.7, 26.5, 7.3 and 2.3 months, respectively (P<0.001) (Fig. 1).
According to multiple regression analysis through Cox 
regression model with the total subjects, the outcome in Table 4 
shows that patients recording a lower grade in Child-Pugh's 
classification and undergoing radiotherapy showed significantly 
longer survival time even after adjusting significant factors 
which were observed in univariate analysis.
As shown in Table 5, the partial analysis for 29 patients 
undergoing radiotherapy by univariate analysis showed that the 
higher an AFP level was, the shorter survival time was 
significantly (P=0.039). Likewise univariate analysis, multiple 
regression analysis which was conducted only for the 
radiotherapy group also revealed that the group with AFP of over 
200 ng/mL had shorter survival time significantly, as shown in 
Table 6.
DISCUSSION
This is a retrospective study which analyzed the survival rate 
by comparing the groups undergoing radiotherapy and only 
palliative care with HCC patients. As mentioned before, the total 
subjects of this study had HCC on the advanced stages, and the 
radiotherapy group received various treatments before and after 
radiotherapy. 
For most patients with advanced HCC, it is difficult to 
treat them actively due to their poor general conditions or 
performance status. If radical treatment is performed for these 
patients excessively, the risk of death following hepatic failure 
can increase easily. That's the reason why non-radical treatments 
are applied. In the radiotherapy group, most patients underwent 
radiotherapy as rescue therapy (28 out of 29, 96.6%). Because of 
it, the response rate of this study or 37.9% was slightly lower than 
that observed overall in previous studies applying the irradiation 
of a similar dose or 40-60%.
4,12,27 196  The Korean Journal of Hepatology Vol. 17. No. 3, September 2011
Table 5. Univariate analysis of overall survival of the subset analysis of the 29 patients treated with radiotherapy (n=29)
Variable N Mean survival (months) P-value
AFP (ng/mL) <200/≥200 20/9 53.4/21.2 0.039
Alcohol drinking Yes/No 20/9 36.9/66.6 0.088
RT target Main-mass/PVT/LN/Main mass+PVT+LN 11/12/5/1 68.4/29.8/26.8/67 0.064
RT response CR/PR/NR/PD 4/7/8/10 49.0/57.3/28.8/42.4 0.236
RT response category Responder/non-responder 11/18 61.9/36.6 0.064
Kaplan-Meier method or log-rank test were used for statistical analysis. 
AFP, alpha fetoprotein; PVT, portal vein thrombosis; LN, lymph node; CR, complete response; PR, partial response; NR, no 
response; PD, progressive disease; RT, radiotherapy.
Table 6. Multivariate analysis for overall survival for the subset analysis of the 29 patients treated with radiotherapy (n=29)
Variables Wald Hazard ratio (95% confidence interval) P-value
Gender (female vs. male) 0.12 1.26 (0.34-4.75) 0.730
Age (<60 vs. ≥60) 1.49 0.54 (0.20-1.46) 0.222
AFP (ng/mL) (<200/≥200) 4.96 3.30 (1.15-9.42) 0.026
Cox regression analysis was used for statistical analysis. 
AFP, alpha fetoprotein.
Because radiotherapy for HCC utilized the irradiation to 
the whole liver in the past, there were many limitations in 
determining a therapeutic dose due to hepatic failure and side 
effects of irradiation of over a certain dose. However, it was 
found that high-dose irradiation to a localized part of the liver did 
not provoke hepatotoxicity,
17,28,29 and that the therapeutic dose 
could be raised by deciding the range for the therapy selectively. 
In particular, for 3D conformal radiotherapy which was provided 
for most patients in this study, it is well known that it improves 
the survival rate of patients with advanced HCC associated with 
embolism by increasing its therapeutic effect, declining 
side effects and reaching the target radiation dose effectively 
compared to conventional radiotherapy.
11,13,25
Meanwhile, the combination of TACE and local radiotherapy 
has been applied continuously to primary HCC which cannot be 
resected, and its positive outcomes of enhancing the survival rate 
have been reported.
12,30 In particular, antitumor agents, which 
were used during TACE to tumor cells on the tumor margin, 
work as radiosensitizers not only to increase the effect of 
radiotherapy but also to make TACE available by improving 
portal vein thrombosis.
4 In this study, 26 patients out of total 29 
ones in the radiotherapy group (89.7%) underwent TACE before 
and after radiotherapy, which was considered to affect their 
survival rate significantly. As the mechanism was mentioned, 
multivariate analysis including both of TACE and radiotherapy 
was conducted. However, TACE did not produce any significant 
effect on the improvement of the survival rate in the patients who 
were selected on this study.
Although basic characteristics of the two groups were largely 
different in this study, it was only a limitation of a retrospective 
study reviewing the medical record, and the result was considered 
to be unavoidable except for a well-designed prospective study. 
Death causes in most cases were hepatic failure, upper 
gastrointestinal bleeding and hemorrhage caused by ruptured 
tumor following hepatic metastasis of HCC, portal vein 
thrombosis and secondary portal hypertension. Like this, 
whether radiotherapy for much advanced HCC patients is helpful 
in boosting the survival rate could be clinically controversial, this 
study was conducted based on the assumption. Multivariate 
regression analysis with the total subjects found that lower grade 
in Child-Pugh's classification or a representative factor as an 
index of liver function and general condition before treatment 
was associated significantly with longer survival time and 
radiotherapy increased the survival time as well. Multivariate 
regression analysis, as partial analysis with the 29 patients 
undergoing radiotherapy, revealed that higher AFP was a 
prognostic factor related to the decrease of the survival rate. The 
finding was the same as that of previous studies reporting that 
increased AFP would be associated with poor prognosis.
31-33 
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put together, the survival rate of advanced HCC were associated 
with all internal and external factors related to treatments for 
HCC such as the general condition of a patient (Child-Pugh's 
classification), the progression and the burden of a tumor (AFP) 
and radiotherapy. This finding strongly suggests that radiotherapy 
as rescue therapy for portal vein thrombosis or primary lump and 
regional nodal metastasis as well as efforts to improve the 
general condition should be provided to increase the survival rate 
of HCC patients.
As a retrospective study reviewing such medical records as 
this study has a possibility of selection bias, it should be 
considered in interpreting its results. This study divided the 
subjects into two groups receiving various treatments along with 
radiotherapy and doing palliative care by considering its purpose, 
but basic characteristics of the two groups were largely different. 
In addition, this study did not consider complications due to 
toxicity of treatments such as radiotherapy induced liver disease 
(RILD) because it was hard to determine which one increased 
liver enzyme levels in the advanced HCC patients between 
radiotherapy and the disease itself. Moreover, analysis on 
improving the quality of life of in investigating detailed 
symptoms and clinical outcomes of patients after radiotherapy, is 
thought to be necessary.
In conclusion, if radiotherapy is available for HCC patients by 
synthesizing their general condition and tumor-related factors, 
an appropriate radiotherapy is expected to increase the survival 
rate. In particular, based on the results of this study when there 
was no distant metastasis that the type is not diffuse, AFP is less 
than 200 ng/mL, and the grade of Child-Pugh's classification 
is A or B in advanced HCC patients, radiotherapy should be 
considered actively as its effect so as to improve the survival rate 
is higher in the cases. 
Prospective studies, analyzing the usefulness of radiotherapy 
to boost the survival rate by comparing patients with similar 
clinical characteristics who were treated with radiotherapy and 
not done, are more necessary in the future. Furthermore, as 
the outcomes of tomotherapy as well as of the previous 3D 
conformal radiotherapy have been reported continuously, 
prospective studies applying them and analyzing the treatment 
group and the non-treatment group, are expected.
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